Christopher Sorli

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 648 citations · Full text

Diabetes Management, Sustain 1, Diabetes +7

Basal expression of cyclooxygenase-2 and nuclear factor–interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet

Christopher Sorli, Huijian Zhang, Michael B. Armstrong et al. · Proceedings of the National Academy of Sciences · 1998 · 140 citations · Full text

Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes

Leonardo Rodríguez, Eliana Reyes, Pilar Fagalde et al. · Diabetes Technology & Therapeutics · 2009 · 131 citations

NOD mice have a generalized defect in their response to transplantation tolerance induction.

Thomas G. Markees, David Serreze, Nancy E. Phillips et al. · Diabetes · 1999 · 115 citations

Cell Therapy, Immune Tolerance, Transplantation Medicine +22

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 94 citations · Full text

Obesity, Metabolic Syndrome, Camellia-timi 61 +9